Archives
IgA Nephropathy – From Pathogenesis To Current Management
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
IgA Nephropathy – From Pathogenesis To Current Management
This presentation is an overview of IgA Nephropathy (IgAN), the most common primary glomerular nephropathy worldwide. During this presentation you will learn the clinical presentation, diagnosis, prognosis, and unmet treatment needs of IgAN. You will then take a deep dive into the current understanding of IgAN pathogenesis including the four hit cascade and the key role B-cells and APRIL (A PRoliferation-Inducing Ligand) play in driving disease progression.
Featuring
Molly Jansen, PhD
Dr Molly Jansen is a Nephrology Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization, Inc. covering South Texas. Molly earned her Doctor of Philosophy degree in Biomedical Science from Wake Forest School of Medicine located in Winston-Salem, NC. While in graduate school, Molly worked as a Business Development Intern at Wake Forest Innovations, fostering the collaborative innovation between industry and the faculty and staff of Wake Forest Baptist Medical Center. After graduate school, Molly did a brief Medical Writing Fellowship with Impact Pharmaceutical Services. Prior to joining Otsuka, Molly worked at Reata Pharmaceuticals, Inc. where she helped to oversee the conduct of clinical trials across a variety of therapeutic areas including nephrology, neurology, and pulmonary, which is where she developed her passion for rare disease.
*Dr Jansen is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC).